• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

作者信息

Tefferi Ayalew, Guglielmelli Paola, Lasho Terra L, Gangat Naseema, Ketterling Rhett P, Pardanani Animesh, Vannucchi Alessandro M

机构信息

Ayalew Tefferi, Mayo Clinic, Rochester, MN; Paola Guglielmelli, University of Florence, Florence, Italy; Terra L. Lasho, Naseema Gangat, Rhett P. Ketterling, and Animesh Pardanani, Mayo Clinic, Rochester, MN; and Alessandro M. Vannucchi, University of Florence, Florence, Italy.

出版信息

J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30.

DOI:10.1200/JCO.2018.78.9867
PMID:29708808
Abstract
摘要

相似文献

1
MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.MIPSS70+ 版本2.0：原发性骨髓纤维化的突变与核型增强国际预后评分系统
J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30.
2
Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.原发性骨髓纤维化：诊断、危险分层和治疗的 2019 更新。
Am J Hematol. 2018 Dec;93(12):1551-1560. doi: 10.1002/ajh.25230. Epub 2018 Oct 26.
3
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.MIPSS70：原发性骨髓纤维化移植年龄患者的突变增强国际预后评分系统。
J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.
4
Myelofibrosis Treatment Algorithm 2018.2018 年骨髓纤维化治疗算法。
Blood Cancer J. 2018 Jul 31;8(8):72. doi: 10.1038/s41408-018-0109-0.
5
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.GIPSS：原发性骨髓纤维化的基因启发预后评分系统。
Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.
6
Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.原发性骨髓纤维化中JAK2V617F突变状态与临床血液学特征及国际预后评分系统评分的相关性：单中心经验
Indian J Pathol Microbiol. 2015 Apr-Jun;58(2):187-91. doi: 10.4103/0377-4929.155311.
7
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.原发性骨髓纤维化中非驱动基因突变和变异等位基因频率的预后影响。
Am J Hematol. 2024 Apr;99(4):755-758. doi: 10.1002/ajh.27203. Epub 2024 Jan 30.
8
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.原发性骨髓纤维化：2013 年诊断、风险分层和治疗更新。
Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384.
9
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.原发性和继发性骨髓纤维化的临床和分子特征比较：MIPSS70+ v2.0 优于 MYSEC-PM。
Am J Hematol. 2024 Apr;99(4):741-744. doi: 10.1002/ajh.27226. Epub 2024 Jan 26.
10
Prognosis of Primary Myelofibrosis in the Genomic Era.基因组时代原发性骨髓纤维化的预后
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S105-13. doi: 10.1016/j.clml.2016.02.031.

引用本文的文献

1
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.芦可替尼治疗的中危-1风险骨髓纤维化患者的修订版“iRR6”模型
Cancer. 2025 Sep 1;131(17):e70062. doi: 10.1002/cncr.70062.
2
Prognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study.红细胞分布宽度与白蛋白比值在骨髓纤维化中的预后意义：一项为期10年的多中心回顾性研究
J Inflamm Res. 2025 Jul 15;18:9229-9242. doi: 10.2147/JIR.S527476. eCollection 2025.
3
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.
2025年亚洲骨髓增殖性肿瘤大会亮点：骨髓增殖性肿瘤分子发病机制与治疗策略的进展
Curr Hematol Malig Rep. 2025 Jul 12;20(1):9. doi: 10.1007/s11899-025-00752-3.
4
BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis.BIRC5上调增强DNMT3A突变型T细胞急性淋巴细胞白血病细胞的存活能力和发病机制。
Blood Neoplasia. 2024 Sep 5;1(4):100040. doi: 10.1016/j.bneo.2024.100040. eCollection 2024 Dec.
5
A molecular signature predicts hematologic evolution in polycythemia vera patients.一种分子特征可预测真性红细胞增多症患者的血液学演变。
Leukemia. 2025 Jun 18. doi: 10.1038/s41375-025-02660-0.
6
Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms.主要骨髓增殖性肿瘤诊断与治疗的当前进展
Cancers (Basel). 2025 May 30;17(11):1834. doi: 10.3390/cancers17111834.
7
Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms.基因组图谱有助于预测BCR-ABL阴性骨髓增殖性肿瘤的克隆演变和预后。
Transl Oncol. 2025 Aug;58:102441. doi: 10.1016/j.tranon.2025.102441. Epub 2025 Jun 9.
8
Allogeneic Transplantation for Older Adults.老年人的异体移植
Adv Exp Med Biol. 2025;1475:9-40. doi: 10.1007/978-3-031-84988-6_2.
9
Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis.仅使用鲁索替尼与联合使用干扰素治疗骨髓纤维化患者的疗效比较。
Blood Neoplasia. 2025 Mar 3;2(2):100082. doi: 10.1016/j.bneo.2025.100082. eCollection 2025 May.
10
and myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice.并且髓系肿瘤相关热点突变在小鼠中诱导出不同的造血表型。
Res Sq. 2025 May 7:rs.3.rs-6377810. doi: 10.21203/rs.3.rs-6377810/v1.